表紙:Follitropin alfa:バイオシミラーの洞察(2020年)
市場調査レポート
商品コード
973901

Follitropin alfa:バイオシミラーの洞察(2020年)

Follitropin alfa- Biosimilar Insight, 2020

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
Follitropin alfa:バイオシミラーの洞察(2020年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、バイオシミラー:Follitropin alfaについて調査しており、10社以上の企業と10製品以上の市販薬およびパイプライン薬に関する包括的な洞察、臨床・非臨床段階の製品を含む市販およびパイプラインの薬剤プロファイル、製品タイプ、段階、投与経路、分子タイプ別の治療法の評価、市場の成長要因や障壁、競合情勢などの情報を提供しています。

当レポート記載の企業

  • Biocad
  • Finox Biotech
  • CinnaGen
  • Dong-A ST
  • Gema Biotech S.A.
  • MinaPharm Pharmaceuticals
  • IVFarma
  • Merck Serono
  • Teva Pharma
  • Theramex
  • AbbVie
  • Itero Biopharmaceuticals
  • Cadila Healthcare

当レポート掲載の主な製品

  • Bemfola
  • Cinnal-F
  • DA-3801
  • Folitime
  • Follitropin-alpha
  • Ovaleap
  • Primapur

目次

第1章 重要な洞察

第2章 スナップショット

第3章 エグゼクティブサマリー

  • 概要
  • 生物製剤の基礎
  • ジェネリック医薬品とバイオシミラー
  • バイオシミラーの経済学:低価格の約束、実際の費用
  • 患者がバイオシミラーについて知っておくべきこと

第4章 バイオシミラーの規制の見通し

  • 北米
    • 米国
    • カナダ
  • 欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
  • その他の地域
    • ブラジル
    • メキシコ
    • アルゼンチン
    • サウジアラビア

第5章 Follitropin alfa(参照製品:Gonal-F)

  • 薬剤のプロファイル
  • 製品の概要
  • 規制当局の承認と立ち上げ
  • 適応症
  • 作用機序
  • 投薬と管理
  • 投与量と強み
  • 用量変更
  • 合成経路
  • 薬理学
  • 薬力学
  • 薬物動態
  • 副作用
  • 製品のスナップショット
  • 開発のマイルストーン

第6章 研究開発

  • 臨床試験情報
  • 安全性と有効性

第7章 Gonal-Fバイオシミラー:新たな機会

第8章 Follitropin alfa:バイオシミラーの評価

  • 製品タイプ別の評価
  • 投与経路別の評価
  • 分子タイプ別の評価
  • 販売別の評価

第9章 企業プロファイル

    • Finox Biotech
    • iVFarma

第10章 比較情勢:企業別

第11章 競合情勢

    • 概要
    • 市場シェア分析
    • 競合シナリオ

第12章 市場の成長要因

第13章 市場の障壁

第14章 SWOT分析

第15章 付録

  • 調査手法

第16章 参考文献

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Products for Follitropin alfa
  • Table 2: Late Stage Products
  • Table 3: Mid Stage Products
  • Table 4: Early Stage Products
  • Table 5: Pre-clinical & Discovery Stage Products
  • Table 6: Assessment by Product Type
  • Table 7: Assessment by Stage and Product Type
  • Table 8: Assessment by Route of Administration
  • Table 9: Assessment by Stage and Route of Administration
  • Table 10: Assessment by Molecule Type
  • Table 11: Assessment by Stage and Molecule Type
  • Table 12: Inactive Products

List of Figures

  • Figure 1: Total Products for Follitropin alfa
  • Figure 2: Late Stage Products
  • Figure 3: Mid Stage Products
  • Figure 4: Early Stage Products
  • Figure 5: Preclinical and Discovery Stage Products
  • Figure 6: Assessment by Product Type
  • Figure 7: Assessment by Stage and Product Type
  • Figure 8: Assessment by Route of Administration
  • Figure 9: Assessment by Stage and Route of Administration
  • Figure 10: Assessment by Molecule Type
  • Figure 11: Assessment by Stage and Molecule Type
  • Figure 12: Inactive Products
目次

DelveInsight's, "Follitropin alfa- Biosimilar Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Follitropin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Follitropin alfa Understanding

Follitropin alfa: Overview

Gonal-f (follitropin alfa for injection) is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the α- and B-subunits. The α- and B-subunits have 92 and 111 amino acids, respectively, and their primary and tertiary structure are indistinguishable from those of human follicle stimulating hormone. Recombinant FSH production occurs in genetically modified Chinese Hamster Ovary (CHO) cells cultured in bioreactors. Purification by immunochromatography using an antibody specifically binding FSH results in a highly purified preparation with a consistent FSH isoform profile, and a high specific activity.

Follitropin alfa Biosimilars: Drugs Chapters

This segment of the Follitropin alfa report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Follitropin alfa Biosimilars: Marketed Drugs

  • Bemfola: Gedeon Richter

Bemfola is a medicine that contains the active substance follitropin alfa. It is used to treat the following groups: women who do not produce eggs and who do not respond to treatment with clomiphene citrate (another medicine that stimulates the ovaries to produce eggs)

Further product details are provided in the report:

Follitropin alfa Biosimilars: Emerging Drugs

  • Primapur: IVFarma

IVFarma is developing Primapur for the treatment of Female infertility.

Further product details are provided in the report:

Follitropin alfa: Therapeutic Assessment

This segment of the report provides insights about the different Follitropin alfa biosimilars segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Follitropin alfa

There are approx. 10+ key companies which are developing the therapies for Follitropin alfa.

  • Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like:

  • Marketed stage products
  • Late stage products (BLA Filed and Phase III)
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Follitropin alfa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Subcutaneous
  • Intravenous
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Follitropin alfa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Follitropin alfa biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follitropin alfa biosimilar drugs.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Follitropin alfa R&D. The therapies under development are focused on novel approaches to treat/improve Follitropin alfa.

Follitropin alfa Biosimilars Report Insights

  • Follitropin alfa Biosimilar Pipeline Analysis
  • Therapeutic Assessment
  • Sales Assessment
  • Unmet Needs
  • Impact of Drugs

Follitropin alfa Biosimilar Report Assessment

  • Marketed Product profiles
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Sales Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Follitropin alfa Biosimilars?
  • How many Follitropin alfa biosimilars are developed by each company?
  • How many emerging biosimilars are in mid-stage, and late-stage?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Follitropin alfa biosimilars therapeutics?
  • What are the clinical studies going on for Follitropin alfa biosimilars and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Biocad
  • Finox Biotech
  • CinnaGen
  • Dong-A ST
  • Gema Biotech S.A.
  • MinaPharm Pharmaceuticals
  • IVFarma
  • Merck Serono
  • Teva Pharma
  • Theramex
  • AbbVie
  • Itero Biopharmaceuticals
  • Cadila Healthcare

Key Products

  • Bemfola
  • Cinnal-F
  • DA-3801
  • Folitime
  • Follitropin-alpha
  • Ovaleap
  • Primapur

Table of Contents

1. Key Insights

2. Follitropin alfa Biosimilars: Snapshot

3. Executive Summary

  • 3.1. Overview
  • 3.2. The Basics of Biologics.
  • 3.3. Biosimilars are not the Same as Generic Drugs
  • 3.4. Economics of Biosimilars - the Promise of Lower Prices, but at What Cost?
  • 3.5. What Patients Need to Know About Biosimilars

4. Regulatory Outlook For Biosimilars

  • 4.1. North America
    • 4.1.1. US
    • 4.1.2. Canada
  • 4.2. Europe
  • 4.3. Asia Pacific
    • 4.3.1. China
    • 4.3.2. India
    • 4.3.3. Japan
    • 4.3.4. South Korea
    • 4.3.5. Australia
  • 4.4. Rest Of The World
    • 4.4.1. Brazil
    • 4.4.2. Mexico
    • 4.4.3. Argentina
    • 4.4.4. Saudi Arabia

More Countries would be added in the final report

5. Follitropin alfa (Reference Product: Gonal-F)

  • 5.1. Drug Profile
  • 5.2. Product Overview
  • 5.3. Regulatory Approvals and Launch
  • 5.4. Indications
  • 5.5. Mechanism of Action
  • 5.6. Dosage and Administration
  • 5.7. Dosage and Strengths
  • 5.8. Dose Modification
  • 5.9. Route of Synthesis
  • 5.10. Pharmacology
  • 5.11. Pharmacodynamics
  • 5.12. Pharmacokinetics
  • 5.13. Adverse Reactions
  • 5.14. Product Snapshot
  • 5.15. Development Milestones

6. Research and Development

  • 6.1. Clinical Trials Information
  • 6.2. Safety and Efficacy

7. Gonal-F Biosimilar: Emerging Opportunities

8. Follitropin alfa: Biosimilars Assessment

  • 8.1. Assessment by Product Type
  • 8.2. Assessment by Route of Administration
  • 8.3. Assessment by Molecule type
  • 8.4. Sales Assessment

9. Follitropin alfa Biosimilars Profiles: By Company

    • 9.1.1. Finox Biotech
      • 9.1.1.1. Bemfola: Finox Biotech
      • 9.1.1.1.1. Product Information
      • 9.1.1.1.2. Research and Development
      • 9.1.1.1.3. Other Development Activities
      • 9.1.1.1.4. General Description Table
    • 9.1.2. iVFarma
      • 9.1.2.1. Primapur: iVFarma
      • 9.1.2.1.1. Product Information
      • 9.1.2.1.2. Research and Development
      • 9.1.2.1.3. Other Development Activities
      • 9.1.2.1.4. General Description Table

More Companies and products would be added in the final report

10. Follitropin alfa Biosimilars: Comparative Landscape: By Company

11. Follitropin alfa Biosimilars: Competitive Landscape

    • 11.1.1. Overview
    • 11.1.2. Market Share Analysis
    • 11.1.3. Competitive Scenario
      • 11.1.3.1. Product Launches and approval
      • 11.1.3.2. Partnerships, Collaborations and Agreements
      • 11.1.3.3. Acquisitions
      • 11.1.3.4. Expansions
      • 11.1.3.5. Patent Expiration of Biologics

More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix

  • 15.1. Research Methodology
    • 15.1.1. Coverage
    • 15.1.2. Secondary Research

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight